Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA)

Ipsen logo

Ipsen

Status and phase

Terminated
Phase 2

Conditions

Acromegaly

Treatments

Drug: BIM 23A760

Study type

Interventional

Funder types

Industry

Identifiers

NCT00994214
2009-010787-42 (EudraCT Number)
2-55-52060-003

Details and patient eligibility

About

The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.

Enrollment

109 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • IGF-1 ≥1.3 x upper limit normal (ULN)
  • Nadir serum GH concentration ≥0.4 ng/mL in an oral glucose tolerance test (OGTT)
  • Patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulin-like growth factor-1 (IGF-1) levels.

Exclusion criteria

  • The patient has received long acting somatostatin analogues within 6 months of study entry
  • The patient has undergone radiotherapy at any time prior to study entry
  • The time between pituitary surgery (if any) and study entry is less than 6 weeks
  • The patient suffers from macroadenoma with visual field defects due to chiasmatic compression

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

109 participants in 4 patient groups

BIM 23A760 1 mg
Experimental group
Treatment:
Drug: BIM 23A760
BIM 23A760 2 mg
Experimental group
Treatment:
Drug: BIM 23A760
BIM 23A760 4 mg
Experimental group
Treatment:
Drug: BIM 23A760
BIM 23A760 6 mg
Experimental group
Treatment:
Drug: BIM 23A760

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems